lenalidomide has been researched along with incb-018424 in 11 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (incb-018424) | Trials (incb-018424) | Recent Studies (post-2010) (incb-018424) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 1,487 | 185 | 1,451 |
| Protein | Taxonomy | lenalidomide (IC50) | incb-018424 (IC50) |
|---|---|---|---|
| Cyclin-G-associated kinase | Homo sapiens (human) | 0.12 | |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0573 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.0001 | |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | 0.0327 | |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.0962 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.3547 | |
| AP2-associated protein kinase 1 | Homo sapiens (human) | 0.1 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.015 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Birgegård, G | 1 |
| Borthakur, G; Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Verstovsek, S; Wang, X; Zhou, L | 1 |
| Aylı, M; Cengiz Seval, G; Özcan, M | 1 |
| Braga, WMT; Colleoni, GWB; Davies, FE; de Carvalho, MF; de Oliveira, MB; Eugenio, AIP; Fernando, RC; Fook-Alves, VL; Sanson, LFG | 1 |
| Cameron, H; Drennan, AC; Kellicut, A; Kelm, A; Kimpara, S; Li, Y; Lu, L; Rui, L; Rumball, I; Selzer, C; Waldmann, TA; Wang, F; Zhang, M; Zhu, F | 1 |
| Björkholm, M; He, J; Liwing, J; Löfgren, C; Schain, F; Song, C; Vago, E | 1 |
| Berenson, JR; Ghermezi, M; Spektor, TM | 1 |
| Berenson, JR; Eades, BM; Eshaghian, S; Ghermezi, M; Lim, S; Martinez, D; Moss, RA; Sanchez, A; Schwartz, G; Spektor, TM; Stampleman, L; Swift, RA; To, J; Turner, C; Vescio, R | 1 |
| Berenson, JR; Bujarski, S; Eades, BR; Emamy-Sadr, M; Green, T; Souther, E; Spektor, TM; Sutanto, C; Swift, RA; To, J | 1 |
| Ahlgrimm, M; Bewarder, M; Bittenbring, JT; Brill, K; Cetin, O; Christofyllakis, K; Kaddu-Mulindwa, D; Kiefer, M; Kos, IA; Lohse, S; Neumann, F; Smola, S; Thurner, L | 1 |
2 review(s) available for lenalidomide and incb-018424
| Article | Year |
|---|---|
Does anything work for anaemia in myelofibrosis?
Topics: Androgens; Anemia; Blood Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Interferons; Lenalidomide; Nitriles; Oxymetholone; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Thalidomide | 2014 |
The role of JAK inhibitors in multiple myeloma.
Topics: Dexamethasone; Humans; Janus Kinase 1; Janus Kinase 2; Lenalidomide; Methylprednisolone; Multiple Myeloma; Neoplasm Proteins; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
4 trial(s) available for lenalidomide and incb-018424
| Article | Year |
|---|---|
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Thalidomide; Treatment Outcome | 2015 |
Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway.
Topics: Aged; Busulfan; Danazol; Disease-Free Survival; Female; Follow-Up Studies; Glucocorticoids; Humans; Hydroxyurea; Lenalidomide; Male; Middle Aged; Nitriles; Norway; Pregnancy; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Registries; Survival Rate; Sweden | 2019 |
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Janus Kinase 1; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitriles; Pyrazoles; Pyrimidines; Survival Rate | 2020 |
Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Cell Maturation Antigen; Dexamethasone; Humans; Lenalidomide; Methylprednisolone; Multiple Myeloma; Nitriles; Prospective Studies; Pyrazoles; Pyrimidines | 2022 |
5 other study(ies) available for lenalidomide and incb-018424
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
Topics: Aged; Aspergillosis; Blood Transfusion; Danazol; Disease Progression; Drug Resistance; Fatal Outcome; Humans; Hydroxyurea; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid, Acute; Male; Nitriles; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Splenectomy; Splenic Infarction; Thalidomide | 2015 |
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Coculture Techniques; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction; STAT Transcription Factors; Stromal Cells; Thalidomide; Time Factors | 2017 |
Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cytokines; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Immunologic Factors; Interferon Type I; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Thalidomide | 2018 |
Adaptive humoral immune response and cellular immune status in cancer patients and patients under immunosuppression vaccinated against SARS-CoV-2.
Topics: Antibodies, Viral; Autoimmune Diseases; COVID-19; COVID-19 Vaccines; Humans; Immunity, Humoral; Immunosuppression Therapy; Lenalidomide; Neoplasms; SARS-CoV-2; Tumor Necrosis Factor Inhibitors | 2022 |